Skip to main content

Table 3 Change1 in seropositive OD ratios between baseline (BL) and follow-up (FU)2 for BL seropositive cases

From: Human papillomavirus serologic follow-up response and relationship to survival in head and neck cancer: a case-comparison study

Change1 in OD Ratio

HPV-16 E6 N = 22

HPV-16 E7

n = 20

 

n (%)

n (%)

BL to FU1

  

   No decrease

8 (36.6)

10 (50.0)

   Decrease

14 (63.4)

10 (50.0)

p-value 3

0.10

0.50

BL to FU2

  

   No decrease

3 (25.0)

4 (36.4)

   Decrease

9 (75.0)

7 (63.6)

p-value 3

0.04

0.19

BL to last FU

  

   No decrease

6 (27.3)

7 (35.0)

   Decrease

16 (72.7)

13 (65.0)

p-value 3

0.02

0.09

  1. 1Based on ≥ 2-fold titration change using the last titration at each follow-up. 2FU1 = follow-up 1, FU2 = follow-up 2, FU = last follow-up, 3One-sided p-values for the binomial test that the proportion of patients who decreased was > 0.50.
Back to article page

Infectious Agents and Cancer

ISSN: 1750-9378

Contact us